Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

Kallesh D. Jayappa, PhD, Caroline Farrington, PhD, Vicki L. Gordon, BS, Shekhar Saha, PhD, Christopher Morris, BS, Krista M. Isaac, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Goutham Narla, MD PhD, Michael J. Weber, PhD

Blood (2020) 136 (Supplement 1): 15–17.

https://doi.org/10.1182/blood-2020-138954

Published: 2020

Journal Articles

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Konrad J. Cios, BSc (2019), Vicki L. Gordon, BSc, Puja C. Arora, MD, Timothy P. Bender, PhD, Michael E. Williams, MD, Craig A. Portell, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 4120.

https://doi.org/10.1182/blood-2018-99-119521

Published: 2018

Journal Articles

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L. Gordon, BSc, Goutham Narla, MD PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2018) 132 (Supplement 1): 2649.

https://doi.org/10.1182/blood-2018-99-116759

Published: 2018

Journal Articles

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Craig A. Portell, MD, Robert W Chen, MD, Nolan Wages, PhD, Jonathon B. Cohen, MD, Michael J. Weber, PhD, Gina Petroni, PhD, Brad S. Kahl, MD, Michael E Williams, MD

Blood (2016) 128 (22): 2958.

https://doi.org/10.1182/blood.V128.22.2958.2958

Published: 2016

Journal Articles

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Kallesh D. Jayappa, DVM, PhD, Craig A. Portell, MD, Vicki L Gordon, BS, Brian J Capaldo, PhD, Stefan Bekiranov, PhD, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2016) 128 (22): 754.

https://doi.org/10.1182/blood.V128.22.754.754

Published: 2016

Journal Articles

Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199)

Kallesh D. Jayappa, PhD, Craig A. Portell, MD, Vicki Gordon, B.S., Michael E. Williams, MD, Emanuel F. Petricoin, PhD, Timothy P. Bender, PhD, Michael J. Weber, PhD

Blood (2015) 126 (23): 448.

https://doi.org/10.1182/blood.V126.23.448.448

Published: 2015

Journal Articles

Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions

Craig A. Portell, MD, Mark Axelrod, PhD, L. Kyle Brett, MD, Vicki L Gordon, BS, Brian Capaldo, Jeffrey C Xing, Stephan Bekiranov, PhD, Michael E. Williams, MD, Michael J. Weber, PhD

Blood (2014) 124 (21): 509.

https://doi.org/10.1182/blood.V124.21.509.509

Published: 2014

Journal Articles

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

L. Kyle Brett, MD, Mark Axelrod, PhD, Zhishuo Ou, MD, Liang Zhang, MD, PhD, Vicki Gordon, BS, Elyse R Lopez, Archito T. Tamayo, MS, Richard J. Ford, MD, PhD, Lan V Pham, PhD, Michael J. Weber, PhD, Michael E. Williams, MD, ScM, Michael Wang, MD

Blood (2013) 122 (21): 3080.

https://doi.org/10.1182/blood.V122.21.3080.3080

Published: 2013

NARROW

Modulation of the Tumor Suppressor Protein PP2A Using a Small Molecule Agonist Overcomes Multi-Drug Resistance through Mitochondrial Permeability Transition Pore (MPTP) Dependent Induction of Apoptosis in Chronic Lymphocytic Leukemia

A Multi-Drug Tolerant Phenotype Is Induced By Diverse Microenvironmental Agonists in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas

Initial Report of a Multi-Institution Phase I/Ib Study of Ibrutinib with Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma

Extrinsic Factors in the In Vivo Macroenvironment Generate Phenotypic Resistance to BTK/Bcl-2 Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Ligands That Mimic the Tissue Microenvironment of Replicating Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) Protect Ex Vivo Patient Cell Samples from the Cytotoxicity of Combined Treatment with Ibrutinib and Venetoclax (ABT-199)

Synergistic Cytotoxicity of Ibrutinib and the BCL2 Antagonist, ABT-199(GDC-0199) in Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL): Molecular Analysis Reveals Mechanisms of Target Interactions

Drug Screening Reveals That Ibrutinib (PCI-32765) Exhibits Synergy With BCL-2 and Proteasome Inhibitors In Models Of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only